Science Explorer Back to mapMap
Discussion
Company · Pittsfield · United States

Nuclea Biotechnologies (United States)

ROR OpenAlex
Research works
5
fractional, all time
Citations
176
38.4 per fractional work
Top-10% rate
13.5%
all institutions 10.0%
Open access
14%
world 40%
International
13%
world 18%
Nuclea Biotechnologies (United States)

Not ranked overall: Nuclea Biotechnologies (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Nuclea Biotechnologies (United States) work in?

In all years, 65% of research at Nuclea Biotechnologies (United States) is in Life Sciences, 20% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (54%), Medicine (20%), Immunology and Microbiology (11%). It does 1.6× the world's share of Life Sciences.

Life Sciences: 3 fractional works · 65.2% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 54.3% of its workImmunology and Microbiology: 0 fractional works · 10.9% of its workHealth Sciences: 1 fractional works · 19.6% of its workMedicine: 1 fractional works · 19.6% of its workPhysical Sciences: 1 fractional works · 15.2% of its workChemistry: 0 fractional works · 10.9% of its workPhysics and Astronomy: 0 fractional works · 4.3% of its workALL ITS WORKNucleaBiotechnologies…5fractional works, all years
Life Sciences65%Physical Sciences15%Health Sciences20%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 5 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology254.3%
    2. Immunology and Microbiology010.9%
    1. Medicine119.6%
    1. Chemistry010.9%
    2. Physics and Astronomy04.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Nuclea Biotechnologies (United States)?

The most cited paper from Nuclea Biotechnologies (United States) is "Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene." (Sheryl L. Brown-Shimer, Karen A. Johnson, DAVID EDWIN HILL et al., 1992), with 144 citations. Next come "Opposing activities of oncogenic MIR17HG and tumor suppressive MIR100HG clusters and their gene targets regulate replicative senescence in human adult stem cells" (23) and "Temperature shift effect on the Chlorobaculum tepidum chlorosomes" (9).

Most cited papers
#PaperReleasedCitations
1 Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene. Sheryl L. Brown-Shimer, Karen A. Johnson, DAVID EDWIN HILL et al. · PubMed 15 Jan 1992 144
2 Opposing activities of oncogenic MIR17HG and tumor suppressive MIR100HG clusters and their gene targets regulate replicative senescence in human adult stem cells Mary F. Lopez, Ping Niu, Lu Wang et al. · npj Aging and Mechanisms of Disease Open access 17 Apr 2017 23
3 Temperature shift effect on the Chlorobaculum tepidum chlorosomes Joseph Kuo‐Hsiang Tang, Ying Xu, Guillermo M. Muhlmann et al. · Photosynthesis Research 22 Feb 2013 9
All 3 most cited papers, with filters and sorting

Which research topics does Nuclea Biotechnologies (United States) publish most on?

By volume: TGF-β signaling in diseases, Bone health and treatments, Advanced Proteomics Techniques and Applications and Cancer, Hypoxia, and Metabolism.

TGF-β signaling in diseases: 0 fractional worksBone health and treatments: 0 fractional worksAdvanced Proteomics Tech…0Advanced Proteomics Techniques and Applications: 0 fractional worksCancer, Hypoxia, and Metabolism: 0 fractional worksRNA modifications and cancer: 0 fractional worksProtease and Inhibitor Mechanisms: 0 fractional worksCancer-related Molecular Pathways: 0 fractional worksNeutrophil, Myeloperoxid…0Neutrophil, Myeloperoxidase and Oxidative Mechanisms: 0 fractional worksProtein Tyrosine Phosphatases: 0 fractional worksCancer, Lipids, and Metabolism: 0 fractional works
Molecular BiologyOncologySpectroscopyCancer Research1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 TGF-β signaling in diseases Molecular Biology 0 works
  2. 2 Bone health and treatments Oncology 0 works
  3. 3 Advanced Proteomics Techniques and Applications Spectroscopy 0 works
  4. 4 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
  5. 5 RNA modifications and cancer Molecular Biology 0 works
  6. 6 Protease and Inhibitor Mechanisms Cancer Research 0 works
  7. 7 Cancer-related Molecular Pathways Oncology 0 works
  8. 8 Neutrophil, Myeloperoxidase and Oxidative Mechanisms Immunology 0 works
  9. 9 Protein Tyrosine Phosphatases Molecular Biology 0 works
  10. 10 Cancer, Lipids, and Metabolism Cancer Research 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available13.7%not open86.3%

World: 40% of research is openly available.

with international co-authors12.6%domestic only87.4%

World: 18% is written across borders.

How has Nuclea Biotechnologies (United States)'s research output changed?

19952000200520102015
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Pittsfield

All research institutions in Pittsfield

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Nuclea Biotechnologies (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.